Recent Updates
Recently added Catalysts
REGN

Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference

Key Takeaway: Regeneron Announces Presentation at the 28th Annual J.P. Morgan Healthcare Conference

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y., Jan. 7 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq:REGN) will webcast its presentation at the 28th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2010. The presentation is scheduled for 1:00 p.m. Eastern Time. The session may be accessed through the Company's web site,www.regeneron.com, on the Investor Relations page. An archived version of the presentation will be available after the live webcast through February 12, 2010. Additional information about Regeneron and recent news releases are available on the Regeneron web site.
Regeneron is a fully integrated biopharmaceutical company that discovers, develops, and commercializes medicines for the treatment of serious medical conditions. In addition to ARCALYST® (rilonacept) Injection for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders.
Last updated: Jan 7, 2010